DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Nestle - 1 Stallergenes Greer - 1 John Revill - 1 Friederike Heine Our - 1
Top related locs:
Brisbane , California Swiss
Top related orgs:
Aimmune Therapeutics - 1 REUTERS - 1 Rights - 1 Nestle - 1 Thomson - 1 & $ - 1

Search resuls for: "Aimmune Therapeutics"


3 mentions found


☆ Nestle divests peanut allergy business Palforzia
  + stars: | 2023-09-04 | by ( ) www.reuters.com   time to read: +1 min
Capsules of Palforzia are shown containing pharmaceutical grade peanut powder, for use in oral immunotherapy among patients with peanut allergies, manufactured by Aimmune Therapeutics, based in Brisbane, California, in this handout obtained by Reuters on February 5, 2020. Aimmune Therapeutics/Handout via REUTERS/File Photo Acquire Licensing RightsZURICH, Sept 4 (Reuters) - Nestle (NESN.S) has divested its peanut allergy treatment business Palforzia, the Swiss food company said on Monday, following its strategic review of the division. Nestle said it has offloaded Palforzia to Stallergenes Greer, a biopharmaceutical company which specializes in the diagnosis and treatment of allergies. Nestle will receive milestone payments and ongoing royalties from Stallergenes Greer, it said. Reporting by John Revill, Editing by Friederike HeineOur Standards: The Thomson Reuters Trust Principles.
Persons: Nestle, Stallergenes Greer, John Revill, Friederike Heine Our Organizations: Aimmune Therapeutics, Reuters, REUTERS, Rights, Nestle, Thomson Locations: Brisbane , California, Swiss
☆ A former AncestryDNA exec launched a startup to 'put an end to allergies.' Here's the pitch deck he used to raise $16.5 million from investors.
  + stars: | 2023-03-08 | by ( Samantha Stokes | ) www.businessinsider.com   time to read: +2 min
Nectar just raised $16.5 million from Harmony Partners, Juxtapose, and Obvious Ventures. The allergy startup was founded by former AncestryDNA executive Kenneth Chahine. The startup just raised a $16.5 million Series A funding round led by Harmony Ventures. They include Y Combinator alum Wyndly, which is expanding access to allergy drops, and Allermi, which prescribes customized allergy sprays. Check out the 34-slide presentation Nectar used to raise its $16.5 million Series A:
☆ Nestlé U-turn is refreshing example of M&A candour
  + stars: | 2022-11-29 | by ( ) www.reuters.com   time to read: +2 min
It’s less common for them to admit as much and reverse tack after just two years. Nestlé originally touted potential annual sales of $1 billion for the drug, which had received U.S. Food and Drug Administration approval. Nestlé Chief Executive Mark Schneider can arguably afford to be honest, rather than trying to bury the M&A flop within his $330 billion behemoth. That’s because his overall acquisition strategy seems to be working. They do not reflect the views of Reuters News, which, under the Trust Principles, is committed to integrity, independence, and freedom from bias.
Organizations: & $
0 next >>
Total: 3